Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

BACKGROUND: Obesity and type 2 diabetes are drivers of non‐alcoholic fatty liver disease (NAFLD). Glucagon‐like peptide‐1 analogues effectively treat obesity and type 2 diabetes and may offer potential for NAFLD treatment. AIM: To evaluate the effect of the glucagon‐like peptide‐1 analogue, semaglut...

Descripción completa

Detalles Bibliográficos
Autores principales: Newsome, Philip, Francque, Sven, Harrison, Stephen, Ratziu, Vlad, Van Gaal, Luc, Calanna, Salvatore, Hansen, Morten, Linder, Martin, Sanyal, Arun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Impact of Semaglutide on Liver Enzymes and Inflammation in Type 2 Diabetes and Obesity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617813/
https://www.ncbi.nlm.nih.gov/pubmed/31246368
http://dx.doi.org/10.1111/apt.15316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617813/
https://www.ncbi.nlm.nih.gov/pubmed/31246368
http://dx.doi.org/10.1111/apt.15316

Ejemplares similares